These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33909124)

  • 1. Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?
    Manoutcharian K; Guzman Valle J; Gevorkian G
    Arch Immunol Ther Exp (Warsz); 2021 Apr; 69(1):12. PubMed ID: 33909124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen Vaccines Pass the Immunogenicity Test.
    Linette GP; Carreno BM
    Trends Mol Med; 2017 Oct; 23(10):869-871. PubMed ID: 28867556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
    Fritsch EF; Burkhardt UE; Hacohen N; Wu CJ
    Cancer Immunol Res; 2020 Dec; 8(12):1465-1469. PubMed ID: 33262163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    Lancaster EM; Jablons D; Kratz JR
    Genet Test Mol Biomarkers; 2020 Feb; 24(2):59-66. PubMed ID: 30907630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Prediction and Validation of Tumor-Associated Neoantigens.
    Roudko V; Greenbaum B; Bhardwaj N
    Front Immunol; 2020; 11():27. PubMed ID: 32117226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens.
    Chi WY; Hu Y; Huang HC; Kuo HH; Lin SH; Kuo CJ; Tao J; Fan D; Huang YM; Wu AA; Hung CF; Wu TC
    J Biomed Sci; 2024 Oct; 31(1):94. PubMed ID: 39379923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries.
    Servín-Blanco R; Chávaro-Ortiz RM; Zamora-Alvarado R; Martínez-Cortes F; Gevorkian G; Manoutcharian K
    Immunol Lett; 2018 Dec; 204():47-54. PubMed ID: 30339819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity.
    Fennemann FL; de Vries IJM; Figdor CG; Verdoes M
    Front Immunol; 2019; 10():824. PubMed ID: 31040852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.
    Wu DW; Jia SP; Xing SJ; Ma HL; Wang X; Tang QY; Li ZW; Wu Q; Bai M; Zhang XY; Fu XF; Jia MM; Tang Y; Chen L; Li N
    Clin Exp Med; 2024 Sep; 24(1):229. PubMed ID: 39325256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
    PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neoantigens derived from transposable elements - A hidden treasure for cancer immunotherapy.
    Hu Z; Guo X; Li Z; Meng Z; Huang S
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189126. PubMed ID: 38849060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
    Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.